merck oral glp-1 Pill Orforglipron More Effective Than Rybelsus in Late-Stage Diabetes Trial Doctors weigh in on GLP-1

According to FDA prescribing information, these effects vary by product and dose: For Ozempic (diabetes treatment): Nausea (15-20% of patients) Diarrhea (8-9% of patients) Vomiting (5-9% of patients) Constipation (3-7% of patients) Abdominal pain (5-6% of patients) For Wegovy (weight management), gastrointestinal effects are more common at the higher therapeutic dose: Nausea (up to 44% of patients) Diarrhea (up to 30% of patients) Vomiting (up to 24% of patients) Constipation (up to 24% of patients) Abdominal pain (up to 20% of patients) These effects are generally mild to moderate and tend to diminish with continued use

Fat-rich diets, for instance, elicit hypothalamic inflammation (reactive activation and proliferation of microglia, a condition named gliosis)

This creates a meaningful connection between gut health and GLP-1 therapy

The actual settlement amounts will depend heavily on bellwether trial outcomes and the strength of causation evidence presented by medical experts

Some clinics offer free initial consultations and payment plans

Some microdosing programs leverage compounded vials marketed at lower monthly prices